Literature DB >> 22966129

Waning antibody levels and avidity: implications for MMR vaccine-induced protection.

Mia Kontio1, Sari Jokinen, Mikko Paunio, Heikki Peltola, Irja Davidkin.   

Abstract

BACKGROUND: The measles-mumps-rubella (MMR) vaccine is effective in eliciting a good antibody response. In addition to the amount of antibodies, the avidity of these antibodies might be important in protecting against disease.
METHODS: The amount of circulating antibodies for measles, mumps, and rubella was measured with enzyme immunoassays, and the avidity of these antibodies was determined by urea dissociation. Three groups of twice-MMR-vaccinated individuals and 1 group of naturally infected individuals were studied. One vaccinated group (n = 71) was studied 6 months and 20 years after a second MMR vaccination.
RESULTS: The antibody avidity indexes were high for measles and rubella but low for mumps. Twenty years after a second MMR vaccination, antibody levels for all 3 viruses waned. Also, the mean avidity index decreased by 8% for measles, 24% for mumps, and remained unchanged for rubella. Antibody avidity correlated with antibody concentration for measles. There was partial correlation for rubella and no correlation for mumps.
CONCLUSIONS: Measles and rubella induced high-avidity antibodies and mumps induced low-avidity antibodies after both vaccination and natural infection. Waning of both the concentration as well as the avidity of antibodies might contribute to measles and mumps infections in twice-MMR-vaccinated individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22966129     DOI: 10.1093/infdis/jis568

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  54 in total

1.  Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome.

Authors:  Terri B Hyde; Helena Keico Sato; LiJuan Hao; Brendan Flannery; Qi Zheng; Kathleen Wannemuehler; Flávia Helena Ciccone; Heloisa de Sousa Marques; Lily Yin Weckx; Marco Aurélio Sáfadi; Eliane de Oliveira Moraes; Marisa Mussi Pinhata; Jaime Olbrich Neto; Maria Cecilia Bevilacqua; Alfredo Tabith Junior; Tatiana Alves Monteiro; Cristina Adelaide Figueiredo; Jon K Andrus; Susan E Reef; Cristiana M Toscano; Carlos Castillo-Solorzano; Joseph P Icenogle
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

2.  Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.

Authors:  Xin-Xing Gu; Stanley A Plotkin; Kathryn M Edwards; Alessandro Sette; Kingston H G Mills; Ofer Levy; Andrea J Sant; Annie Mo; William Alexander; Kristina T Lu; Christopher E Taylor
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

3.  In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.

Authors:  T N Figueira; L M Palermo; A S Veiga; D Huey; C A Alabi; N C Santos; J C Welsch; C Mathieu; B Horvat; S Niewiesk; A Moscona; M A R B Castanho; M Porotto
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

4.  DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Authors:  Surender Khurana; Jian Wu; Milena Dimitrova; Lisa R King; Jody Manischewitz; Barney S Graham; Julie E Ledgerwood; Hana Golding
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

5.  Measles epidemic from 1951 to 2012 and vaccine effectiveness in Guangzhou, southern China.

Authors:  Zhicong Yang; Jianxiong Xu; Ming Wang; Biao Di; Huifeng Tan; Qing He; Yanshan Cai; Jianhua Liang; Wensui Hu; Zhiqiang Dong; Yunqing Yang; Chuanxi Fu
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

6.  Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers.

Authors:  Luca Coppeta; Ottavia Balbi; Savino Baldi; Antonio Pietroiusti; Andrea Magrini
Journal:  Hum Vaccin Immunother       Date:  2019-03-27       Impact factor: 3.452

Review 7.  Measles Vaccine.

Authors:  Diane E Griffin
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

8.  Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides.

Authors:  C Mathieu; D Huey; E Jurgens; J C Welsch; I DeVito; A Talekar; B Horvat; S Niewiesk; A Moscona; M Porotto
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

9.  Viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain.

Authors:  Irene Barrabeig; Josep Costa; Ariadna Rovira; M Angeles Marcos; Ricard Isanta; Rubén López-Adalid; Ana Cervilla; Nuria Torner; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

10.  Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.

Authors:  Karen K Yam; Jyotsana Gupta; Angela Brewer; David W Scheifele; Scott Halperin; Brian J Ward
Journal:  Clin Vaccine Immunol       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.